• Shattuck Labs’ SL-325 Phase 2b Crohn’s disease trial is ongoing, with 12-week induction data expected in the first half of 2028.
• A Phase 2b hidradenitis suppurativa trial is expected to start in fourth-quarter 2026, with 16-week data due in first-half 2028.
• SL-325’s completed Phase 1 trial showed no serious adverse events; the anti-drug antibody rate was 3.7%.
• SL-846 Phase 1 initiation is planned for the first half of 2027, with initial data expected that year.
• Cash, cash equivalents and short-term investments totaled $196.3 million at September 30, 2026, supporting planned operations into 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.